Chemicals
Showing 19201–19350 of 41137 results
-
Eupenifeldin is a pentacyclic bistropolone fungal metabolite originally isolated from E. brefeldianum ATCC 74184.{39755} It is cytotoxic against HCT116 and HCTVM46 colon carcinoma cells in vitro (IC50s = 0.005 and 0.002 μg/ml, respectively). In vivo, eupenifeldin (0.3-2 mg/kg per day) increases median survival time in a mouse model of P388 leukemia.
Brand:CaymanSKU:25114 - 500 µgAvailable on backorder
Euphol acetate is a triterpenoid that has been found in Euphorbia species and has diverse biological activities.{48815,48816,48817} It reduces sodium fluorescein uptake by CHO cells expressing organic anion-transporting polypeptide 1B1 (OATP1B1) and OATP1B3 to 29.2 and 40.2% of controls, respectively, when used at a concentration of 10 μM.{48817} Euphol acetate (50 and 100 μg/ml) induces mortality in 40% of B. glabrata snails.{48816}
Brand:CaymanSKU:29646 - 1 mgAvailable on backorder
Euphorbiasteroid is a tricyclic diterpene that has been found in the plant E. lathyris.{48442} It inhibits early-stage adipogenesis of 3T3-L1 cells, decreasing intracellular triglyceride accumulation when used at concentrations of 25 and 50 µM.{48443} It decreases the expression of Fas, C/EBPα, PPARγ, and SREBP-1c and increases phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC) in 3T3-L1 cells. Euphorbiasteroid inhibits proliferation of HL-60 cells in a concentration-dependent manner, as well as induces apoptosis and increases the expression of Fas and Fas ligand (FasL) and the activity of caspase-3 and caspase-8 in HL-60 cells.{48444} It increases P-glycoprotein activity, reverses multi-drug resistance, and restores cytotoxicity of the anticancer agents vinblastine (Item No. 11762), paclitaxel (Item No. 10461), and doxorubicin (Item No. 15007) to MES-SA/Dx5 sarcoma cells.{48445}
Brand:CaymanSKU:27822 - 100 mgAvailable on backorder
Euphorbiasteroid is a tricyclic diterpene that has been found in the plant E. lathyris.{48442} It inhibits early-stage adipogenesis of 3T3-L1 cells, decreasing intracellular triglyceride accumulation when used at concentrations of 25 and 50 µM.{48443} It decreases the expression of Fas, C/EBPα, PPARγ, and SREBP-1c and increases phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC) in 3T3-L1 cells. Euphorbiasteroid inhibits proliferation of HL-60 cells in a concentration-dependent manner, as well as induces apoptosis and increases the expression of Fas and Fas ligand (FasL) and the activity of caspase-3 and caspase-8 in HL-60 cells.{48444} It increases P-glycoprotein activity, reverses multi-drug resistance, and restores cytotoxicity of the anticancer agents vinblastine (Item No. 11762), paclitaxel (Item No. 10461), and doxorubicin (Item No. 15007) to MES-SA/Dx5 sarcoma cells.{48445}
Brand:CaymanSKU:27822 - 25 mgAvailable on backorder
Euphorbiasteroid is a tricyclic diterpene that has been found in the plant E. lathyris.{48442} It inhibits early-stage adipogenesis of 3T3-L1 cells, decreasing intracellular triglyceride accumulation when used at concentrations of 25 and 50 µM.{48443} It decreases the expression of Fas, C/EBPα, PPARγ, and SREBP-1c and increases phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC) in 3T3-L1 cells. Euphorbiasteroid inhibits proliferation of HL-60 cells in a concentration-dependent manner, as well as induces apoptosis and increases the expression of Fas and Fas ligand (FasL) and the activity of caspase-3 and caspase-8 in HL-60 cells.{48444} It increases P-glycoprotein activity, reverses multi-drug resistance, and restores cytotoxicity of the anticancer agents vinblastine (Item No. 11762), paclitaxel (Item No. 10461), and doxorubicin (Item No. 15007) to MES-SA/Dx5 sarcoma cells.{48445}
Brand:CaymanSKU:27822 - 250 mgAvailable on backorder
Euphorbiasteroid is a tricyclic diterpene that has been found in the plant E. lathyris.{48442} It inhibits early-stage adipogenesis of 3T3-L1 cells, decreasing intracellular triglyceride accumulation when used at concentrations of 25 and 50 µM.{48443} It decreases the expression of Fas, C/EBPα, PPARγ, and SREBP-1c and increases phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC) in 3T3-L1 cells. Euphorbiasteroid inhibits proliferation of HL-60 cells in a concentration-dependent manner, as well as induces apoptosis and increases the expression of Fas and Fas ligand (FasL) and the activity of caspase-3 and caspase-8 in HL-60 cells.{48444} It increases P-glycoprotein activity, reverses multi-drug resistance, and restores cytotoxicity of the anticancer agents vinblastine (Item No. 11762), paclitaxel (Item No. 10461), and doxorubicin (Item No. 15007) to MES-SA/Dx5 sarcoma cells.{48445}
Brand:CaymanSKU:27822 - 50 mgAvailable on backorder
Eurycomanone is a quassinoid originally isolated from E. longifolia that has diverse biological activities.{59000} It is active against the W2 and D6 clones of P. falciparum (IC50s = 0.015 and 0.026 µg/ml, respectively).{59002} Eurycomanone induces lipolysis in 3T3-L1 adipocytes with an EC50 value of 14.6 µM, an effect that can be blocked by the protein kinase A (PKA) inhibitor H-89 (Item No. 10010556).{59001} It induces cell cycle arrest at the G2/M phase and apoptosis in HepG2 cells when used at a concentration of 5 µg/ml.{59003} It reduces estrogen release and increases testosterone release in isolated rat Leydig cell-rich testicular interstitial cell preparations when used at concentrations of 1 and 10 µM.{59004} Eurycomanone (1 mg/kg, i.p.) decreases gastric acid secretion and lesion size in rat models of indomethacin-, water immersion stress-, or pyloric ligation-induced ulcer formation.{59005}
Brand:CaymanSKU:30896 - 1 mgAvailable on backorder
Eurycomanone is a quassinoid originally isolated from E. longifolia that has diverse biological activities.{59000} It is active against the W2 and D6 clones of P. falciparum (IC50s = 0.015 and 0.026 µg/ml, respectively).{59002} Eurycomanone induces lipolysis in 3T3-L1 adipocytes with an EC50 value of 14.6 µM, an effect that can be blocked by the protein kinase A (PKA) inhibitor H-89 (Item No. 10010556).{59001} It induces cell cycle arrest at the G2/M phase and apoptosis in HepG2 cells when used at a concentration of 5 µg/ml.{59003} It reduces estrogen release and increases testosterone release in isolated rat Leydig cell-rich testicular interstitial cell preparations when used at concentrations of 1 and 10 µM.{59004} Eurycomanone (1 mg/kg, i.p.) decreases gastric acid secretion and lesion size in rat models of indomethacin-, water immersion stress-, or pyloric ligation-induced ulcer formation.{59005}
Brand:CaymanSKU:30896 - 10 mgAvailable on backorder
Eurycomanone is a quassinoid originally isolated from E. longifolia that has diverse biological activities.{59000} It is active against the W2 and D6 clones of P. falciparum (IC50s = 0.015 and 0.026 µg/ml, respectively).{59002} Eurycomanone induces lipolysis in 3T3-L1 adipocytes with an EC50 value of 14.6 µM, an effect that can be blocked by the protein kinase A (PKA) inhibitor H-89 (Item No. 10010556).{59001} It induces cell cycle arrest at the G2/M phase and apoptosis in HepG2 cells when used at a concentration of 5 µg/ml.{59003} It reduces estrogen release and increases testosterone release in isolated rat Leydig cell-rich testicular interstitial cell preparations when used at concentrations of 1 and 10 µM.{59004} Eurycomanone (1 mg/kg, i.p.) decreases gastric acid secretion and lesion size in rat models of indomethacin-, water immersion stress-, or pyloric ligation-induced ulcer formation.{59005}
Brand:CaymanSKU:30896 - 25 mgAvailable on backorder
Eurycomanone is a quassinoid originally isolated from E. longifolia that has diverse biological activities.{59000} It is active against the W2 and D6 clones of P. falciparum (IC50s = 0.015 and 0.026 µg/ml, respectively).{59002} Eurycomanone induces lipolysis in 3T3-L1 adipocytes with an EC50 value of 14.6 µM, an effect that can be blocked by the protein kinase A (PKA) inhibitor H-89 (Item No. 10010556).{59001} It induces cell cycle arrest at the G2/M phase and apoptosis in HepG2 cells when used at a concentration of 5 µg/ml.{59003} It reduces estrogen release and increases testosterone release in isolated rat Leydig cell-rich testicular interstitial cell preparations when used at concentrations of 1 and 10 µM.{59004} Eurycomanone (1 mg/kg, i.p.) decreases gastric acid secretion and lesion size in rat models of indomethacin-, water immersion stress-, or pyloric ligation-induced ulcer formation.{59005}
Brand:CaymanSKU:30896 - 5 mgAvailable on backorder
Evacetrapib is a benzazepine inhibitor of cholesteryl ester transfer protein (CETP; IC50s = 5.5 and 26 nM for human recombinant and plasma-derived proteins, respectively).{41797} It is selective for CETP over a panel of cell surface and nuclear receptors with no significant inhibition at 1 µM. Evacetrapib (1-10 µM) reduces expression of the serine protease proprotein convertase subtilisin kexin 9 (PCSK9) and the LDL receptor (LDLR) in HepG2 cells in a dose-dependent manner with no effect on cell viability.{41798} It also reduces protein levels of LDLR, SREBF2-M, and PCSK9 in HepG2 lysates, nuclear extracts, and culture medium, respectively, in a dose-dependent manner. Oral administration of evacetrapib (30 mg/kg) inhibits CETP activity by 98.5, 98.6, and 18.4% after four, eight, and 24 hours, respectively, in serum from transgenic mice expressing human CETP and ApoA1.{41797} Evacetrapib increases HDL cholesterol levels in CETP/ApoA1 transgenic mice in a dose-dependent manner, including by 129.7% eight hours following administration of a 30 mg/kg dose.
Brand:CaymanSKU:23670 - 10 mgAvailable on backorder
Evacetrapib is a benzazepine inhibitor of cholesteryl ester transfer protein (CETP; IC50s = 5.5 and 26 nM for human recombinant and plasma-derived proteins, respectively).{41797} It is selective for CETP over a panel of cell surface and nuclear receptors with no significant inhibition at 1 µM. Evacetrapib (1-10 µM) reduces expression of the serine protease proprotein convertase subtilisin kexin 9 (PCSK9) and the LDL receptor (LDLR) in HepG2 cells in a dose-dependent manner with no effect on cell viability.{41798} It also reduces protein levels of LDLR, SREBF2-M, and PCSK9 in HepG2 lysates, nuclear extracts, and culture medium, respectively, in a dose-dependent manner. Oral administration of evacetrapib (30 mg/kg) inhibits CETP activity by 98.5, 98.6, and 18.4% after four, eight, and 24 hours, respectively, in serum from transgenic mice expressing human CETP and ApoA1.{41797} Evacetrapib increases HDL cholesterol levels in CETP/ApoA1 transgenic mice in a dose-dependent manner, including by 129.7% eight hours following administration of a 30 mg/kg dose.
Brand:CaymanSKU:23670 - 100 mgAvailable on backorder
Evacetrapib is a benzazepine inhibitor of cholesteryl ester transfer protein (CETP; IC50s = 5.5 and 26 nM for human recombinant and plasma-derived proteins, respectively).{41797} It is selective for CETP over a panel of cell surface and nuclear receptors with no significant inhibition at 1 µM. Evacetrapib (1-10 µM) reduces expression of the serine protease proprotein convertase subtilisin kexin 9 (PCSK9) and the LDL receptor (LDLR) in HepG2 cells in a dose-dependent manner with no effect on cell viability.{41798} It also reduces protein levels of LDLR, SREBF2-M, and PCSK9 in HepG2 lysates, nuclear extracts, and culture medium, respectively, in a dose-dependent manner. Oral administration of evacetrapib (30 mg/kg) inhibits CETP activity by 98.5, 98.6, and 18.4% after four, eight, and 24 hours, respectively, in serum from transgenic mice expressing human CETP and ApoA1.{41797} Evacetrapib increases HDL cholesterol levels in CETP/ApoA1 transgenic mice in a dose-dependent manner, including by 129.7% eight hours following administration of a 30 mg/kg dose.
Brand:CaymanSKU:23670 - 5 mgAvailable on backorder
Evacetrapib is a benzazepine inhibitor of cholesteryl ester transfer protein (CETP; IC50s = 5.5 and 26 nM for human recombinant and plasma-derived proteins, respectively).{41797} It is selective for CETP over a panel of cell surface and nuclear receptors with no significant inhibition at 1 µM. Evacetrapib (1-10 µM) reduces expression of the serine protease proprotein convertase subtilisin kexin 9 (PCSK9) and the LDL receptor (LDLR) in HepG2 cells in a dose-dependent manner with no effect on cell viability.{41798} It also reduces protein levels of LDLR, SREBF2-M, and PCSK9 in HepG2 lysates, nuclear extracts, and culture medium, respectively, in a dose-dependent manner. Oral administration of evacetrapib (30 mg/kg) inhibits CETP activity by 98.5, 98.6, and 18.4% after four, eight, and 24 hours, respectively, in serum from transgenic mice expressing human CETP and ApoA1.{41797} Evacetrapib increases HDL cholesterol levels in CETP/ApoA1 transgenic mice in a dose-dependent manner, including by 129.7% eight hours following administration of a 30 mg/kg dose.
Brand:CaymanSKU:23670 - 50 mgAvailable on backorder
Evernic acid is a secondary metabolite produced by some species of lichen that can bind to allosteric sites on the protein surface of FAS-II enzymes and produce antibacterial and antiplasmodial effects.{28468} It inhibits two key plasmodial FAS-II enzymes PfFabZ and PfFabI (IC50 = 10.7 and 36.1 µM, respectively) but shows low efficacy against the malaria parasite P. berghei (IC50 = 77.3 µM).{28468}
Brand:CaymanSKU:-Available on backorder
Evernic acid is a secondary metabolite produced by some species of lichen that can bind to allosteric sites on the protein surface of FAS-II enzymes and produce antibacterial and antiplasmodial effects.{28468} It inhibits two key plasmodial FAS-II enzymes PfFabZ and PfFabI (IC50 = 10.7 and 36.1 µM, respectively) but shows low efficacy against the malaria parasite P. berghei (IC50 = 77.3 µM).{28468}
Brand:CaymanSKU:-Available on backorder
Evernic acid is a secondary metabolite produced by some species of lichen that can bind to allosteric sites on the protein surface of FAS-II enzymes and produce antibacterial and antiplasmodial effects.{28468} It inhibits two key plasmodial FAS-II enzymes PfFabZ and PfFabI (IC50 = 10.7 and 36.1 µM, respectively) but shows low efficacy against the malaria parasite P. berghei (IC50 = 77.3 µM).{28468}
Brand:CaymanSKU:-Available on backorder
Evernic acid is a secondary metabolite produced by some species of lichen that can bind to allosteric sites on the protein surface of FAS-II enzymes and produce antibacterial and antiplasmodial effects.{28468} It inhibits two key plasmodial FAS-II enzymes PfFabZ and PfFabI (IC50 = 10.7 and 36.1 µM, respectively) but shows low efficacy against the malaria parasite P. berghei (IC50 = 77.3 µM).{28468}
Brand:CaymanSKU:-Available on backorder
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that, as part of two distinct complexes (mTORC1 and mTORC2), plays pivotal roles in intracellular signaling.{15415,15559,24848} Everolimus is a hydroxyethyl ether rapamycin (Item No. 13346) derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24847,24849} It also acts as an immunosuppressive agent in the context of organ transplantation.{24847,24846}
Brand:CaymanSKU:11597 - 10 mgAvailable on backorder
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that, as part of two distinct complexes (mTORC1 and mTORC2), plays pivotal roles in intracellular signaling.{15415,15559,24848} Everolimus is a hydroxyethyl ether rapamycin (Item No. 13346) derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24847,24849} It also acts as an immunosuppressive agent in the context of organ transplantation.{24847,24846}
Brand:CaymanSKU:11597 - 25 mgAvailable on backorder
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that, as part of two distinct complexes (mTORC1 and mTORC2), plays pivotal roles in intracellular signaling.{15415,15559,24848} Everolimus is a hydroxyethyl ether rapamycin (Item No. 13346) derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24847,24849} It also acts as an immunosuppressive agent in the context of organ transplantation.{24847,24846}
Brand:CaymanSKU:11597 - 5 mgAvailable on backorder
Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus (Item No. 11597) by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin (Item No. 13346) that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24849,24846} It also acts as an immunosuppressive agent in the context of organ transplantation.
Brand:CaymanSKU:22559 -Out of stock
Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus (Item No. 11597) by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin (Item No. 13346) that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24849,24846} It also acts as an immunosuppressive agent in the context of organ transplantation.
Brand:CaymanSKU:22559 -Out of stock
Evobrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 8.9 nM).{50414} It is selective for BTK over a panel of 233 kinases at 1 μM. It inhibits BTK in peripheral blood mononuclear cells (PBMCs; IC50 = 61 nM). Evobrutinib inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively).{46591} It inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis when administered at doses of 3.95, 19.8, and 39.5 mg/kg. Evobrutinib (1 and 3 mg/kg) reduces cartilage destruction in a rat model of collagen-induced arthritis. It also decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of systemic lupus erythematosus (SLE).
Brand:CaymanSKU:29029 - 1 mgAvailable on backorder
Evobrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 8.9 nM).{50414} It is selective for BTK over a panel of 233 kinases at 1 μM. It inhibits BTK in peripheral blood mononuclear cells (PBMCs; IC50 = 61 nM). Evobrutinib inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively).{46591} It inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis when administered at doses of 3.95, 19.8, and 39.5 mg/kg. Evobrutinib (1 and 3 mg/kg) reduces cartilage destruction in a rat model of collagen-induced arthritis. It also decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of systemic lupus erythematosus (SLE).
Brand:CaymanSKU:29029 - 10 mgAvailable on backorder
Evobrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 8.9 nM).{50414} It is selective for BTK over a panel of 233 kinases at 1 μM. It inhibits BTK in peripheral blood mononuclear cells (PBMCs; IC50 = 61 nM). Evobrutinib inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively).{46591} It inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis when administered at doses of 3.95, 19.8, and 39.5 mg/kg. Evobrutinib (1 and 3 mg/kg) reduces cartilage destruction in a rat model of collagen-induced arthritis. It also decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of systemic lupus erythematosus (SLE).
Brand:CaymanSKU:29029 - 25 mgAvailable on backorder
Evobrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 8.9 nM).{50414} It is selective for BTK over a panel of 233 kinases at 1 μM. It inhibits BTK in peripheral blood mononuclear cells (PBMCs; IC50 = 61 nM). Evobrutinib inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively).{46591} It inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis when administered at doses of 3.95, 19.8, and 39.5 mg/kg. Evobrutinib (1 and 3 mg/kg) reduces cartilage destruction in a rat model of collagen-induced arthritis. It also decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of systemic lupus erythematosus (SLE).
Brand:CaymanSKU:29029 - 5 mgAvailable on backorder
Evoxanthine is an alkaloid that has been found in O. renieri and has antimalarial and anticancer activities.{52172,52173} It is active against P. falciparum with an IC50 value of 67.6 µg/ml.{52172} Evoxanthine decreases proliferation of nine sensitive and drug-resistant cancer cell lines (IC50s = 6.11-80.99 µM).{52173}
Brand:CaymanSKU:29437 - 1 mgAvailable on backorder
Evoxanthine is an alkaloid that has been found in O. renieri and has antimalarial and anticancer activities.{52172,52173} It is active against P. falciparum with an IC50 value of 67.6 µg/ml.{52172} Evoxanthine decreases proliferation of nine sensitive and drug-resistant cancer cell lines (IC50s = 6.11-80.99 µM).{52173}
Brand:CaymanSKU:29437 - 5 mgAvailable on backorder
EVP-6124 is a partial agonist of α7 subunit-containing nicotinic acetylcholine receptors (nAChRs; IC50 = 22.38 nM).{52384} It is 1,000-fold selective for α7 subunit-containing nAChRs over α4β2 subunit-containing nAChRs at 10 µM, as well as a panel of 60 peptide and nonpeptide receptors, ion channels, and transporters. EVP-6124 induces inward currents in Xenopus oocytes expressing human α7 subunit-containing nAChRs (EC50 = 0.16 µM). In vivo, EVP-6124 (0.1, 0.3, and 1 mg/kg) reverses scopolamine-induced deficits in the novel object recognition task and prevents natural forgetting of a familiar object in rats. It reduces premature responding, a measure of impulsivity, by low-attentive but not high-attentive female rats in the 5-choice serial reaction time test (5CSRTT).{52385}
Brand:CaymanSKU:30073 - 10 mgAvailable on backorder
EVP-6124 is a partial agonist of α7 subunit-containing nicotinic acetylcholine receptors (nAChRs; IC50 = 22.38 nM).{52384} It is 1,000-fold selective for α7 subunit-containing nAChRs over α4β2 subunit-containing nAChRs at 10 µM, as well as a panel of 60 peptide and nonpeptide receptors, ion channels, and transporters. EVP-6124 induces inward currents in Xenopus oocytes expressing human α7 subunit-containing nAChRs (EC50 = 0.16 µM). In vivo, EVP-6124 (0.1, 0.3, and 1 mg/kg) reverses scopolamine-induced deficits in the novel object recognition task and prevents natural forgetting of a familiar object in rats. It reduces premature responding, a measure of impulsivity, by low-attentive but not high-attentive female rats in the 5-choice serial reaction time test (5CSRTT).{52385}
Brand:CaymanSKU:30073 - 25 mgAvailable on backorder
EVP-6124 is a partial agonist of α7 subunit-containing nicotinic acetylcholine receptors (nAChRs; IC50 = 22.38 nM).{52384} It is 1,000-fold selective for α7 subunit-containing nAChRs over α4β2 subunit-containing nAChRs at 10 µM, as well as a panel of 60 peptide and nonpeptide receptors, ion channels, and transporters. EVP-6124 induces inward currents in Xenopus oocytes expressing human α7 subunit-containing nAChRs (EC50 = 0.16 µM). In vivo, EVP-6124 (0.1, 0.3, and 1 mg/kg) reverses scopolamine-induced deficits in the novel object recognition task and prevents natural forgetting of a familiar object in rats. It reduces premature responding, a measure of impulsivity, by low-attentive but not high-attentive female rats in the 5-choice serial reaction time test (5CSRTT).{52385}
Brand:CaymanSKU:30073 - 5 mgAvailable on backorder
EVP-6124 is a partial agonist of α7 subunit-containing nicotinic acetylcholine receptors (nAChRs; IC50 = 22.38 nM).{52384} It is 1,000-fold selective for α7 subunit-containing nAChRs over α4β2 subunit-containing nAChRs at 10 µM, as well as a panel of 60 peptide and nonpeptide receptors, ion channels, and transporters. EVP-6124 induces inward currents in Xenopus oocytes expressing human α7 subunit-containing nAChRs (EC50 = 0.16 µM). In vivo, EVP-6124 (0.1, 0.3, and 1 mg/kg) reverses scopolamine-induced deficits in the novel object recognition task and prevents natural forgetting of a familiar object in rats. It reduces premature responding, a measure of impulsivity, by low-attentive but not high-attentive female rats in the 5-choice serial reaction time test (5CSRTT).{52385}
Brand:CaymanSKU:30073 - 50 mgAvailable on backorder
EW-7197 is a potent inhibitor of activin receptor-like kinase 5 (ALK5, also known as TGF-β receptor type 1; IC50 = 12.9 nM).{34039,34042} It also inhibits ALK2 and ALK4 at nanomolar concentrations.{34042} EW-7197 blocks TGF-β/Smad signaling, cell migration, invasion, and lung metastasis in mouse mammary tumor virus/c-Neu mice and 4TI orthotopic-grafted mice.{34042} It also inhibits epithelial-to-mesenchymal transition (EMT) in TGF-β-treated breast cancer cells.{34042} EW-7197 is used to block TGF-β signaling and EMT in animal models of cancer and fibrosis.{34040,34041,34043}
Brand:CaymanSKU:-Available on backorder
EW-7197 is a potent inhibitor of activin receptor-like kinase 5 (ALK5, also known as TGF-β receptor type 1; IC50 = 12.9 nM).{34039,34042} It also inhibits ALK2 and ALK4 at nanomolar concentrations.{34042} EW-7197 blocks TGF-β/Smad signaling, cell migration, invasion, and lung metastasis in mouse mammary tumor virus/c-Neu mice and 4TI orthotopic-grafted mice.{34042} It also inhibits epithelial-to-mesenchymal transition (EMT) in TGF-β-treated breast cancer cells.{34042} EW-7197 is used to block TGF-β signaling and EMT in animal models of cancer and fibrosis.{34040,34041,34043}
Brand:CaymanSKU:-Available on backorder
EW-7197 is a potent inhibitor of activin receptor-like kinase 5 (ALK5, also known as TGF-β receptor type 1; IC50 = 12.9 nM).{34039,34042} It also inhibits ALK2 and ALK4 at nanomolar concentrations.{34042} EW-7197 blocks TGF-β/Smad signaling, cell migration, invasion, and lung metastasis in mouse mammary tumor virus/c-Neu mice and 4TI orthotopic-grafted mice.{34042} It also inhibits epithelial-to-mesenchymal transition (EMT) in TGF-β-treated breast cancer cells.{34042} EW-7197 is used to block TGF-β signaling and EMT in animal models of cancer and fibrosis.{34040,34041,34043}
Brand:CaymanSKU:-Available on backorder
Exemestane is a third generation, irreversible steroidal aromatase inhibitor (Ki = 10.2 nM; Kinact = 26 nM) that induces aromatase degradation leading to a decrease in estrogen levels in plasma.{22655,22657} As an androgen analog, exemestane exhibits androgenic effects and has been shown to decrease total and HDL cholesterol, apo A1, and total triglyceride levels.{22656} Marketed under the trade name Aromasin™, exemestane has been used to treat estrogen receptor-positive breast cancers in post-menopausal women.{22655}
Brand:CaymanSKU:- Exemestane is a third generation, irreversible steroidal aromatase inhibitor (Ki = 10.2 nM; Kinact = 26 nM) that induces aromatase degradation leading to a decrease in estrogen levels in plasma.{22655,22657} As an androgen analog, exemestane exhibits androgenic effects and has been shown to decrease total and HDL cholesterol, apo A1, and total triglyceride levels.{22656} Marketed under the trade name Aromasin™, exemestane has been used to treat estrogen receptor-positive breast cancers in post-menopausal women.{22655}
Brand:CaymanSKU:- Exemestane is a third generation, irreversible steroidal aromatase inhibitor (Ki = 10.2 nM; Kinact = 26 nM) that induces aromatase degradation leading to a decrease in estrogen levels in plasma.{22655,22657} As an androgen analog, exemestane exhibits androgenic effects and has been shown to decrease total and HDL cholesterol, apo A1, and total triglyceride levels.{22656} Marketed under the trade name Aromasin™, exemestane has been used to treat estrogen receptor-positive breast cancers in post-menopausal women.{22655}
Brand:CaymanSKU:- Exemestane is a third generation, irreversible steroidal aromatase inhibitor (Ki = 10.2 nM; Kinact = 26 nM) that induces aromatase degradation leading to a decrease in estrogen levels in plasma.{22655,22657} As an androgen analog, exemestane exhibits androgenic effects and has been shown to decrease total and HDL cholesterol, apo A1, and total triglyceride levels.{22656} Marketed under the trade name Aromasin™, exemestane has been used to treat estrogen receptor-positive breast cancers in post-menopausal women.{22655}
Brand:CaymanSKU:-
Exendin-3 (9-39) amide is a truncated form of the exendin-4 (Item No. 11096) peptide that acts as a potent competitive antagonist for the glucagon-like peptide 1 receptor (GLP-1R; Kd = 1.7 nM in CHL cells transfected with cloned human GLP-1).{27504} It inhibits exendin-3-induced increases in cAMP levels in guinea pig pancreas cells (IC50 = 20 nM).{34476} Exendin-3 (9-39) amide administration in the hypothalamus (10 and 100 µg, i.c.v.) reverses GLP-1 inhibition of feeding behavior in rats.{34477}
Brand:CaymanSKU:19890 -Available on backorder
Exendin-3 (9-39) amide is a truncated form of the exendin-4 (Item No. 11096) peptide that acts as a potent competitive antagonist for the glucagon-like peptide 1 receptor (GLP-1R; Kd = 1.7 nM in CHL cells transfected with cloned human GLP-1).{27504} It inhibits exendin-3-induced increases in cAMP levels in guinea pig pancreas cells (IC50 = 20 nM).{34476} Exendin-3 (9-39) amide administration in the hypothalamus (10 and 100 µg, i.c.v.) reverses GLP-1 inhibition of feeding behavior in rats.{34477}
Brand:CaymanSKU:19890 -Available on backorder
Exendin-4 is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor (Ki = 136 pM).{27501,27502,27504,24256} By activating the GLP-1 receptor, it stimulates glucose-induced insulin secretion in isolated rat islets and proinsulin expression in mouse insulinoma βTC-1 cells, supporting efficacy in type 2 diabetes.{27502} Exendin-4 was first isolated from the venom of H. horridum and consequently synthesized, with the recombinant peptide referred to as ‘exenatide.’ Exenatide protects hippocampal neurons against glutamate-induced apoptosis, suggesting utility in neuropathies associated with type 2 diabetes and in neurodegenerative diseases.{27503,27506} Exenatide also has anxiolytic and anti-depressant effects and induces satiety.{27506,27505}
Brand:CaymanSKU:11096 - 1 mgAvailable on backorder
Exendin-4 is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor (Ki = 136 pM).{27501,27502,27504,24256} By activating the GLP-1 receptor, it stimulates glucose-induced insulin secretion in isolated rat islets and proinsulin expression in mouse insulinoma βTC-1 cells, supporting efficacy in type 2 diabetes.{27502} Exendin-4 was first isolated from the venom of H. horridum and consequently synthesized, with the recombinant peptide referred to as ‘exenatide.’ Exenatide protects hippocampal neurons against glutamate-induced apoptosis, suggesting utility in neuropathies associated with type 2 diabetes and in neurodegenerative diseases.{27503,27506} Exenatide also has anxiolytic and anti-depressant effects and induces satiety.{27506,27505}
Brand:CaymanSKU:11096 - 5 mgAvailable on backorder
Exendin-4 is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor (Ki = 136 pM).{27501,27502,27504,24256} By activating the GLP-1 receptor, it stimulates glucose-induced insulin secretion in isolated rat islets and proinsulin expression in mouse insulinoma βTC-1 cells, supporting efficacy in type 2 diabetes.{27502} Exendin-4 was first isolated from the venom of H. horridum and consequently synthesized, with the recombinant peptide referred to as ‘exenatide.’ Exenatide protects hippocampal neurons against glutamate-induced apoptosis, suggesting utility in neuropathies associated with type 2 diabetes and in neurodegenerative diseases.{27503,27506} Exenatide also has anxiolytic and anti-depressant effects and induces satiety.{27506,27505}
Brand:CaymanSKU:11096 - 500 µgAvailable on backorder
Exo1 is a cell-permeable, reversible inhibitor of exocytosis (IC50 = 20 µM).{29668} It interferes with protein trafficking and secretion mediated by the Golgi apparatus and endoplasmic reticulum by dissociating the GTPase activator ADP-ribosylation factor (ARF1) from Golgi membranes, which leads to a consequent collapse of the Golgi apparatus.{29668}
Brand:CaymanSKU:-Available on backorder
Exo1 is a cell-permeable, reversible inhibitor of exocytosis (IC50 = 20 µM).{29668} It interferes with protein trafficking and secretion mediated by the Golgi apparatus and endoplasmic reticulum by dissociating the GTPase activator ADP-ribosylation factor (ARF1) from Golgi membranes, which leads to a consequent collapse of the Golgi apparatus.{29668}
Brand:CaymanSKU:-Available on backorder
Programmed cell death in bacteria is dependent on a system of cell-to-cell communication termed quorum sensing. Extracellular death factor (EDF) is a linear pentapeptide that communicating cells produce and release, which upon reaching a sufficient concentration activates the cell death pathway in a subset of cells.{24994} It is sensitive to extreme pH, high temperatures, and other stressful conditions.{24994} At 2.5 ng/ml, EDF has been shown to facilitate mazEF-mediated cell death, significantly reducing population size in E. coli cultures.{24994}
Brand:CaymanSKU:- Programmed cell death in bacteria is dependent on a system of cell-to-cell communication termed quorum sensing. Extracellular death factor (EDF) is a linear pentapeptide that communicating cells produce and release, which upon reaching a sufficient concentration activates the cell death pathway in a subset of cells.{24994} It is sensitive to extreme pH, high temperatures, and other stressful conditions.{24994} At 2.5 ng/ml, EDF has been shown to facilitate mazEF-mediated cell death, significantly reducing population size in E. coli cultures.{24994}
Brand:CaymanSKU:-
Glutathione S-transferases (GSTs) are ubiquitous multifunctional enzymes that play key roles in cellular detoxification and signal transduction by conjugating target substrates to glutathione. GSTP1-1, the most prevalent GST isozyme in nonhepatic tissues, binds to and inhibits the stress-activated c-Jun N-terminal kinase (JNK), an important regulator of cell proliferation, differentiation, and apoptosis.{27831} GSTP1-1 is overexpressed in many cancers and has been linked to drug resistance.{27832} Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity (Ki = 400 nM) with minimal effect on the related GSTα and -µ families (Kis range from 20-75 µM).{27831} After intracellular de-esterification, the active form of ezatiostat, TLK117, binds to and inhibits GSTP1-1, restoring JNK-mediated cellular proliferation and differentiation signaling pathways.{27832,27833,27834} Ezatiostat has been shown to stimulate the proliferation of myeloid precursors in preclinical models and is under clinical examination for its potential prevention of myelosuppression in myelodysplastic syndrome.{27833,27834}
Brand:CaymanSKU:- Glutathione S-transferases (GSTs) are ubiquitous multifunctional enzymes that play key roles in cellular detoxification and signal transduction by conjugating target substrates to glutathione. GSTP1-1, the most prevalent GST isozyme in nonhepatic tissues, binds to and inhibits the stress-activated c-Jun N-terminal kinase (JNK), an important regulator of cell proliferation, differentiation, and apoptosis.{27831} GSTP1-1 is overexpressed in many cancers and has been linked to drug resistance.{27832} Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity (Ki = 400 nM) with minimal effect on the related GSTα and -µ families (Kis range from 20-75 µM).{27831} After intracellular de-esterification, the active form of ezatiostat, TLK117, binds to and inhibits GSTP1-1, restoring JNK-mediated cellular proliferation and differentiation signaling pathways.{27832,27833,27834} Ezatiostat has been shown to stimulate the proliferation of myeloid precursors in preclinical models and is under clinical examination for its potential prevention of myelosuppression in myelodysplastic syndrome.{27833,27834}
Brand:CaymanSKU:- Glutathione S-transferases (GSTs) are ubiquitous multifunctional enzymes that play key roles in cellular detoxification and signal transduction by conjugating target substrates to glutathione. GSTP1-1, the most prevalent GST isozyme in nonhepatic tissues, binds to and inhibits the stress-activated c-Jun N-terminal kinase (JNK), an important regulator of cell proliferation, differentiation, and apoptosis.{27831} GSTP1-1 is overexpressed in many cancers and has been linked to drug resistance.{27832} Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity (Ki = 400 nM) with minimal effect on the related GSTα and -µ families (Kis range from 20-75 µM).{27831} After intracellular de-esterification, the active form of ezatiostat, TLK117, binds to and inhibits GSTP1-1, restoring JNK-mediated cellular proliferation and differentiation signaling pathways.{27832,27833,27834} Ezatiostat has been shown to stimulate the proliferation of myeloid precursors in preclinical models and is under clinical examination for its potential prevention of myelosuppression in myelodysplastic syndrome.{27833,27834}
Brand:CaymanSKU:- Glutathione S-transferases (GSTs) are ubiquitous multifunctional enzymes that play key roles in cellular detoxification and signal transduction by conjugating target substrates to glutathione. GSTP1-1, the most prevalent GST isozyme in nonhepatic tissues, binds to and inhibits the stress-activated c-Jun N-terminal kinase (JNK), an important regulator of cell proliferation, differentiation, and apoptosis.{27831} GSTP1-1 is overexpressed in many cancers and has been linked to drug resistance.{27832} Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity (Ki = 400 nM) with minimal effect on the related GSTα and -µ families (Kis range from 20-75 µM).{27831} After intracellular de-esterification, the active form of ezatiostat, TLK117, binds to and inhibits GSTP1-1, restoring JNK-mediated cellular proliferation and differentiation signaling pathways.{27832,27833,27834} Ezatiostat has been shown to stimulate the proliferation of myeloid precursors in preclinical models and is under clinical examination for its potential prevention of myelosuppression in myelodysplastic syndrome.{27833,27834}
Brand:CaymanSKU:-
Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.{19679,15337,}Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.{19679,15337} Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.{19679,43023}
Brand:CaymanSKU:-Out of stock
Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.{19679,15337,}Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.{19679,15337} Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.{19679,43023}
Brand:CaymanSKU:-Out of stock
Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.{19679,15337,}Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.{19679,15337} Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.{19679,43023}
Brand:CaymanSKU:-Out of stock
Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.{19679,15337,}Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.{19679,15337} Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.{19679,43023}
Brand:CaymanSKU:-Out of stock
Ezetimibe hydroxy glucuronide is a minor phase II glucuronide metabolite of ezetimibe (Item No. 16331).{47182}
Brand:CaymanSKU:26602 - 1 mgAvailable on backorder
Ezetimibe hydroxy glucuronide is a minor phase II glucuronide metabolite of ezetimibe (Item No. 16331).{47182}
Brand:CaymanSKU:26602 - 500 µgAvailable on backorder
Ezetimibe-d4 is intended for use as an internal standard for the quantification of ezetimibe (Item No. 16331) by GC- or LC-MS. Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.{19679,15337} Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.{19679,15337} Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.{19679,43023}
Brand:CaymanSKU:25044 - 1 mgAvailable on backorder
EZM2302 is an inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 = 6 nM).{53436} It decreases asymmetric methylation of the PRMT4 substrate PABP1 (IC50 = 0.038 µM) and increases levels of demethylated SmB (EC50 = 0.018 µM) in RPMI-8226 multiple myeloma cells. EZM2302 inhibits proliferation in a panel of 36 hematopoietic cancer cell lines, with IC50 values of less than 100 μM for nine of the 15 multiple myeloma cell lines included in the panel. It reduces tumor growth and decreases asymmetric PABP1 methylation in tumor tissue in an RPMI-8226 mouse xenograft model when administered at doses of 75, 150, and 300 mg/kg twice per day. Intrathecal injection of EZM2302 (10 µg) reduces acute mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain induced by chronic constriction injury (CCI).{53437}
Brand:CaymanSKU:29954 - 1 mgAvailable on backorder
EZM2302 is an inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 = 6 nM).{53436} It decreases asymmetric methylation of the PRMT4 substrate PABP1 (IC50 = 0.038 µM) and increases levels of demethylated SmB (EC50 = 0.018 µM) in RPMI-8226 multiple myeloma cells. EZM2302 inhibits proliferation in a panel of 36 hematopoietic cancer cell lines, with IC50 values of less than 100 μM for nine of the 15 multiple myeloma cell lines included in the panel. It reduces tumor growth and decreases asymmetric PABP1 methylation in tumor tissue in an RPMI-8226 mouse xenograft model when administered at doses of 75, 150, and 300 mg/kg twice per day. Intrathecal injection of EZM2302 (10 µg) reduces acute mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain induced by chronic constriction injury (CCI).{53437}
Brand:CaymanSKU:29954 - 10 mgAvailable on backorder
EZM2302 is an inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 = 6 nM).{53436} It decreases asymmetric methylation of the PRMT4 substrate PABP1 (IC50 = 0.038 µM) and increases levels of demethylated SmB (EC50 = 0.018 µM) in RPMI-8226 multiple myeloma cells. EZM2302 inhibits proliferation in a panel of 36 hematopoietic cancer cell lines, with IC50 values of less than 100 μM for nine of the 15 multiple myeloma cell lines included in the panel. It reduces tumor growth and decreases asymmetric PABP1 methylation in tumor tissue in an RPMI-8226 mouse xenograft model when administered at doses of 75, 150, and 300 mg/kg twice per day. Intrathecal injection of EZM2302 (10 µg) reduces acute mechanical allodynia and thermal hyperalgesia in a mouse model of neuropathic pain induced by chronic constriction injury (CCI).{53437}
Brand:CaymanSKU:29954 - 5 mgAvailable on backorder
Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein.{32729} Through this action, ezutromid increases muscle function in dystrophin-deficient mdx mice, a mouse model of muscular dystrophy.{32729} A double-blind, placebo-controlled Phase I study demonstrated that ezutromid is safe and well tolerated in healthy volunteers.{32730}
Brand:CaymanSKU:20309 -Available on backorder
Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein.{32729} Through this action, ezutromid increases muscle function in dystrophin-deficient mdx mice, a mouse model of muscular dystrophy.{32729} A double-blind, placebo-controlled Phase I study demonstrated that ezutromid is safe and well tolerated in healthy volunteers.{32730}
Brand:CaymanSKU:20309 -Available on backorder
Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein.{32729} Through this action, ezutromid increases muscle function in dystrophin-deficient mdx mice, a mouse model of muscular dystrophy.{32729} A double-blind, placebo-controlled Phase I study demonstrated that ezutromid is safe and well tolerated in healthy volunteers.{32730}
Brand:CaymanSKU:20309 -Available on backorder
Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein.{32729} Through this action, ezutromid increases muscle function in dystrophin-deficient mdx mice, a mouse model of muscular dystrophy.{32729} A double-blind, placebo-controlled Phase I study demonstrated that ezutromid is safe and well tolerated in healthy volunteers.{32730}
Brand:CaymanSKU:20309 -Available on backorder
F-14329 is a tetramic acid fungal metabolite and a metal chelator that has been found in Chaunopycnis.{52470} It chelates iron, copper, magnesium, zinc, and aluminum ions in cell-free assays.
Brand:CaymanSKU:29999 - 1 mgAvailable on backorder
F-amidine is an inhibitor of protein arginine deiminases (PADs) that is selective for PAD1 and PAD4 (IC50s = 29.5, 350, and 21.6 µM for PAD1, PAD3, and PAD4 in vitro, respectively).{18132,19982} It irreversibly inactivates all four PAD subtypes (kinact/KI = 2,800, 380, 170, and 3,000 M-1min-1 by covalently modifying an active site cysteine that is important for its catalytic activity.{18132,36047} F-amidine is cytotoxic to HL-60, MCF-7, and HT-29 cancer cell lines (IC50s = 0.5, 0.5 and 1 μM, respectively).{18529}
Brand:CaymanSKU:10610 - 1 mgAvailable on backorder
F-amidine is an inhibitor of protein arginine deiminases (PADs) that is selective for PAD1 and PAD4 (IC50s = 29.5, 350, and 21.6 µM for PAD1, PAD3, and PAD4 in vitro, respectively).{18132,19982} It irreversibly inactivates all four PAD subtypes (kinact/KI = 2,800, 380, 170, and 3,000 M-1min-1 by covalently modifying an active site cysteine that is important for its catalytic activity.{18132,36047} F-amidine is cytotoxic to HL-60, MCF-7, and HT-29 cancer cell lines (IC50s = 0.5, 0.5 and 1 μM, respectively).{18529}
Brand:CaymanSKU:10610 - 100 µgAvailable on backorder
F-amidine is an inhibitor of protein arginine deiminases (PADs) that is selective for PAD1 and PAD4 (IC50s = 29.5, 350, and 21.6 µM for PAD1, PAD3, and PAD4 in vitro, respectively).{18132,19982} It irreversibly inactivates all four PAD subtypes (kinact/KI = 2,800, 380, 170, and 3,000 M-1min-1 by covalently modifying an active site cysteine that is important for its catalytic activity.{18132,36047} F-amidine is cytotoxic to HL-60, MCF-7, and HT-29 cancer cell lines (IC50s = 0.5, 0.5 and 1 μM, respectively).{18529}
Brand:CaymanSKU:10610 - 250 µgAvailable on backorder
F-amidine is an inhibitor of protein arginine deiminases (PADs) that is selective for PAD1 and PAD4 (IC50s = 29.5, 350, and 21.6 µM for PAD1, PAD3, and PAD4 in vitro, respectively).{18132,19982} It irreversibly inactivates all four PAD subtypes (kinact/KI = 2,800, 380, 170, and 3,000 M-1min-1 by covalently modifying an active site cysteine that is important for its catalytic activity.{18132,36047} F-amidine is cytotoxic to HL-60, MCF-7, and HT-29 cancer cell lines (IC50s = 0.5, 0.5 and 1 μM, respectively).{18529}
Brand:CaymanSKU:10610 - 500 µgAvailable on backorder
F16 is a small, cationic, lipophilic molecule which binds preferentially to mitochondrial membranes and disrupts their function.{10295} F16 was discovered in high throughput screens for tumor inhibitors, where it was found to induce apoptosis in HER-1/EGFR-expressing breast carcinoma cell lines. In addition to being a potential antitumor agent, F16 is an easily visualized fluorescent molecule which can also be used to visualize mitochondria under confocal microscopy. The mechanism of apoptosis induction by F16 is believed to be through disruption of the mitochondrial transmembrane potential.{10295}
Brand:CaymanSKU:10022 - 1 mgAvailable on backorder
F16 is a small, cationic, lipophilic molecule which binds preferentially to mitochondrial membranes and disrupts their function.{10295} F16 was discovered in high throughput screens for tumor inhibitors, where it was found to induce apoptosis in HER-1/EGFR-expressing breast carcinoma cell lines. In addition to being a potential antitumor agent, F16 is an easily visualized fluorescent molecule which can also be used to visualize mitochondria under confocal microscopy. The mechanism of apoptosis induction by F16 is believed to be through disruption of the mitochondrial transmembrane potential.{10295}
Brand:CaymanSKU:10022 - 10 mgAvailable on backorder
F16 is a small, cationic, lipophilic molecule which binds preferentially to mitochondrial membranes and disrupts their function.{10295} F16 was discovered in high throughput screens for tumor inhibitors, where it was found to induce apoptosis in HER-1/EGFR-expressing breast carcinoma cell lines. In addition to being a potential antitumor agent, F16 is an easily visualized fluorescent molecule which can also be used to visualize mitochondria under confocal microscopy. The mechanism of apoptosis induction by F16 is believed to be through disruption of the mitochondrial transmembrane potential.{10295}
Brand:CaymanSKU:10022 - 5 mgAvailable on backorder
F16 is a small, cationic, lipophilic molecule which binds preferentially to mitochondrial membranes and disrupts their function.{10295} F16 was discovered in high throughput screens for tumor inhibitors, where it was found to induce apoptosis in HER-1/EGFR-expressing breast carcinoma cell lines. In addition to being a potential antitumor agent, F16 is an easily visualized fluorescent molecule which can also be used to visualize mitochondria under confocal microscopy. The mechanism of apoptosis induction by F16 is believed to be through disruption of the mitochondrial transmembrane potential.{10295}
Brand:CaymanSKU:10022 - 50 mgAvailable on backorder
AM2201 (Item No. 10707) is a potent synthetic cannabinoid (CB) that binds the CB1 and CB2 receptors with high affinity (Kis = 1.0 and 2.6 nM, respectively).{18696} F2201 is an analog of AM2201 with a fluorine at the 4 position of the naphthyl group. The physiological and toxicological properties of this compound have not been delineated. This product is intended for research and forensic purposes.
Brand:CaymanSKU:9001580 - 1 mgAvailable on backorder
AM2201 (Item No. 10707) is a potent synthetic cannabinoid (CB) that binds the CB1 and CB2 receptors with high affinity (Kis = 1.0 and 2.6 nM, respectively).{18696} F2201 is an analog of AM2201 with a fluorine at the 4 position of the naphthyl group. The physiological and toxicological properties of this compound have not been delineated. This product is intended for research and forensic purposes.
Brand:CaymanSKU:9001580 - 10 mgAvailable on backorder
AM2201 (Item No. 10707) is a potent synthetic cannabinoid (CB) that binds the CB1 and CB2 receptors with high affinity (Kis = 1.0 and 2.6 nM, respectively).{18696} F2201 is an analog of AM2201 with a fluorine at the 4 position of the naphthyl group. The physiological and toxicological properties of this compound have not been delineated. This product is intended for research and forensic purposes.
Brand:CaymanSKU:9001580 - 25 mgAvailable on backorder
AM2201 (Item No. 10707) is a potent synthetic cannabinoid (CB) that binds the CB1 and CB2 receptors with high affinity (Kis = 1.0 and 2.6 nM, respectively).{18696} F2201 is an analog of AM2201 with a fluorine at the 4 position of the naphthyl group. The physiological and toxicological properties of this compound have not been delineated. This product is intended for research and forensic purposes.
Brand:CaymanSKU:9001580 - 5 mgAvailable on backorder
FAD is a flavin dinucleotide that is synthesized when the AMP moiety from ATP is transferred onto riboflavin 5′-monophosphate (Item No. 18167).{38399} FAD functions as a coenzyme that facilitates the transfer of electrons by flavoenzymes in oxidation-reduction reactions in cells.{38400} FAD (0.0125-0.05% solution) reduces UV-B-induced death of human corneal epithelial cells in vitro.{38401}
Brand:CaymanSKU:23386 - 100 mgAvailable on backorder